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TOPICAL REVIEW
The neglected role of insulin-like growth factors in the
maternal circulation regulating fetal growth
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1Centre for Trophoblast Research Department of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK
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Maternal insulin-like growth factors (IGFs) play a pivotal role in modulating fetal growth
via their actions on both the mother and the placenta. Circulating IGFs inﬂuence maternal
tissue growth and metabolism, thereby regulating nutrient availability for the growth of
the conceptus. Maternal IGFs also regulate placental morphogenesis, substrate transport and
hormone secretion, all of which inﬂuence fetal growth either via indirect effects on maternal
substrateavailability,orthroughdirecteffectsontheplacentaanditscapacitytosupplynutrients
to the fetus. The extent to which IGFs inﬂuence the mother and/or placenta are dependent on
thespeciesandmaternalfactors,includingageandnutrition.Asalteredfetalgrowthisassociated
with increased perinatal morbidity and mortality and a greater risk of developing degenerative
diseases in adult life, understanding the role of maternal IGFs during pregnancy is essential in
order to identify mechanisms underlying altered fetal growth and offspring programming.
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Introduction
The insulin-like growth factors (IGFs) IGF-I and IGF-II
are 7.5kDa single-chained polypeptides that promote
growth both before and after birth. They affect the
metabolism, mitogenesis and differentiation of a wide
variety of cell types, including those of the placenta by
binding to IGF receptors (IGF1R and IGF2R), insulin
receptor (InsR) and a hybrid IGF1R–InsR receptor. Their
bioavailability is inﬂuenced by at least six IGF binding
proteins (IGFBP-1 to IGFBP-6) that prolong the IGF
half-life in the circulation and transport IGFs to their
receptors. Together, the IGFs, their receptors and binding
proteins form the IGF axis, which is responsive to a range
of environmental signals including nutrients, oxygen
and hormones, such as growth hormone (GH), cortisol,
insulin, thyroid hormones and sex steroids.
Before birth, IGFs are paracrine growth regulators
synthesised by multiple fetal tissues, independently of
GH. Although IGF-II is the most abundant fetal IGF,
deletion of either Igf gene in mice reduces birth weight
to 60% of wildtype (Louvi etal. 1997; Fowden, 2003).
Effects of IGFs on fetal growth are additive, as deletion
of Igf1r, through which both IGFs act, reduces birth
weight to a greater extent than deletion of either Igf1 or
Igf2 alone (Louvi etal. 1997). Whilst IGF-I appears to
regulate fetal growth in response to nutrient availability,
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IGF-II is thought to provide the constitutive stimulus
for feto-placental growth (Fowden, 2003). Circulating
IGF-I concentrations rise after birth due primarily to
the onset of GH-dependent hepatic synthesis of IGF-I
although a variety of other tissues also continue to
produce IGF-I. This endocrine IGF-I production drives
growthpostnatally.Incontrast,IGF-IIexpressiondeclines
towards term in association with pre-partum maturation
of speciﬁc tissues, although IGF-II still circulates in
plasmaofseveralspeciespostnatally(Gargoskyetal.1990;
Giudice etal. 1993; Sohlstrom etal. 1998; Perry etal.
2002). However, in adult mice, IGF-II is conﬁned to
the brain and is not detectable in plasma (Fielder etal.
1990). After postnatal growth is complete, the role of
IGFs is less clear. They are thought to be involved in
the turnover and growth of adult tissues during physio-
logical conditions, such as wound healing, exercise and
pregnancy.ThisreviewexaminesthematernalIGFsystem
during pregnancy and its effects on fetal growth, with
particular emphasis on the actions of IGFs on maternal
metabolism and nutrient partitioning and on placental
growth and function. Since the pattern of fetal growth
determines rates of morbidity and mortality at, and long
after, birth (Barker, 2004), understanding the role of
maternal IGFs during pregnancy may help identify the
mechanisms involved in developmental programming of
life expectancy.
Maternal IGF concentrations
Maternal plasma IGFs during pregnancy depend on
speciesandgestationalage(Fig.1).Inspecieslikehumans,
rabbits and guinea pigs, maternal IGF-I concentrations
increase in the ﬁrst half of pregnancy (Fig.1: Gargosky
etal. 1990; Nason etal. 1996; Sohlstrom etal. 1998).
I nw o m e n ,I G F - Il e v e l sc o n t i n u et or i s et h r o u g h o u t
pregnancy, whilst in rabbits and guinea pigs, the elevated
IGF-I levels decline rapidly from mid-pregnancy onwards
(Fig.1). In the baboon, rhesus monkey, rat and pig,
maternal circulating IGF-I concentrations fall during
pregnancy to as low as 30% of non-pregnant values
(Giudice etal. 1993; Farmer etal. 2000; Van Mieghem
etal. 2009). In some species like cattle and sheep, plasma
IGF-Iisunalteredbypregnancy(Fig.1:Wallaceetal.1997;
Perry etal. 2002; Weber etal. 2007; de Boo etal. 2008). In
micedams,plasmaIGF-Iatmid-pregnancyis∼70%lower
than in virgin and early pregnant females but nothing is
known about concentrations in late pregnancy (Travers
etal. 1990).
The IGF-II proﬁle in maternal plasma is more
consistent across species than for IGF-I, with an over-
all rise in concentrations during pregnancy (Fig.1).
In some animals, the increase is marginal, whereas in
others like rabbits, there is a 200-fold increment by
mid-gestation (Fig.1: Nason etal. 1996). In rat dams,
plasmaIGF-IIincreaseswithadvancinggestation,whereas
in women,levels are maintainedafter the initial elevation,
throughout pregnancy (Fig.1: Gargosky etal. 1990; Van
Mieghemetal.2009).Innon-humanprimatesandrabbits,
maternalplasmaIGF-IIdeclinestowardstermbutremains
higher than non-pregnant values (Fig.1). In cows and
guinea pigs, plasma IGF-II concentrations are relatively
unresponsive to pregnancy (Sohlstrom etal. 1998; Perry
etal. 2002). Irrespective of reproductive state, IGF-II
is more abundant than IGF-I in most species studied
(Gargosky etal. 1990; Giudice etal. 1993; Nason etal.
1996; Sohlstrom etal. 1998).
Sources of maternal IGFs
There are several potential sources of IGFs during
pregnancy.Inseveralspecies,IGFsareproducedbyarange
of tissues that may increase in mass during pregnancy
including the liver, uterus, skeletal muscle and adipose
tissue (Peter etal. 1993; Coleman etal. 1994; Sterle etal.
1998; Olausson & Sohlstrom, 2003). Indeed, in women,
the increased maternal IGF-I concentration in early–mid
pregnancy is thought to reﬂect growth of maternal tissues
(Lof etal. 2005). In rabbits, maternal whole body tissue
growth and subsequent tissue mobilisation are associated
with elevated and then reduced IGFs in early and late
gestation, respectively (Nason etal. 1996). As adipose
tissue accounts for a greater proportion of maternal body
mass during pregnancy, it may contribute signiﬁcantly to
the circulating pool of IGFs. However, as blood volume
rises in parallel with maternal body mass, increased tissue
mass is unlikely to be the sole explanation for the rise in
maternal IGFs during pregnancy.
Studiesperformedmainlyintheguineapighaveshown
thatIgf expressionisincreasedinsome,butnotall,tissues
per unit mass during pregnancy (Sohlstrom etal. 1998;
Olausson & Sohlstrom, 2003). For instance, there is no
increase in Igf mRNA expression by maternal muscle,
although its mass is increased. In contrast, Igf mRNA
abundance in maternal liver and fat increase early in
pregnancy and are maintained until term, especially for
Igf1, despite reductions in hepatic and adipose tissue
weightduringthesecondhalfofpregnancy.Furthermore,
uterine expression of Igf1 mRNA is reduced during
guinea pig pregnancy. Thus, in early pregnancy, an
increase in Igf expression by the liver and adipose
tissue plus expansion of muscle mass in the mother,
may contribute to her elevated plasma IGF-I. In late
pregnancy, the reduced liver and fat mass combined with
down-regulated uterine Igf1 gene expression may explain
the pre-partum decline in plasma IGF-I levels (Sohlstrom
etal. 1998; Olausson & Sohlstrom, 2003). In rats, the
fall in maternal IGF-I concentration, particularly in the
C   2010 The Authors. Journal compilation C   2010 The Physiological SocietyJ Physiol 589.1 Maternal IGF and its regulation in fetal growth 9
second half of pregnancy, coincides with reduced hepatic
Igf1 gene expression (Donovan etal. 1991). In part, the
changes in tissue growth and Igf gene expression during
pregnancy may relate to the altered maternal endocrine
environment.Indeed,somatotropinandsteroidhormone
concentrations alter during pregnancy and are known to
regulate IGF production (Handwerger & Freemark, 2000;
Mullis & Tonella, 2008); however, deﬁnitive studies are
required.
Another potential source of maternal IGFs is the
placenta. In all species studied, the placenta synthesises
IGF-II, at least in early pregnancy. In haemochorial
placentas of humans, guinea pigs, rhesus monkeys,
baboons, rats and mice, IGF-II is produced by the
syncytiotrophoblast layer in direct contact with maternal
blood (Han & Carter, 2000; Nayak & Giudice, 2003;
Sferruzzi-Perrietal.2006).Inrodents,theplacentaislikely
to be a major IGF-II source as Igf2 gene expression is
limited in adult peripheral tissues. In humans, IGF-II is
alsoproducedabundantlybytheextravilloustrophoblasts
lining the uterine spiral arteries (Han & Carter, 2000).
In contrast to IGF-II, the placenta is an unlikely source
of IGF-I as it expresses very little (Han & Carter,
2000). However, the placenta may inﬂuence maternal
plasma IGF-I indirectly through secreting hormones
which modulate IGF-I synthesis in maternal tissues. For
instance, human syncytiotrophoblast secretes a variant
of growth hormone, placental growth hormone (PGH),
which stimulates maternal IGF-I production despite a fall
in pituitary GH secretion (Alsat etal. 1998). Similarly, the
placentasecretesplacentallactogen(PL)intothematernal
circulation, which is thought to modulate maternal IGF-I
expression, although direct evidence for this is limited
(Handwerger & Freemark, 2000; Karabulut etal. 2001).
ChangesinmaternalcirculatingIGFsduringpregnancy
may also be due to post-translational processes. In
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Figure 1. The changes in maternal circulating concentrations of IGF-I (A) and IGF-II (B) during pregnancy
expressed as a percentage of the non-pregnant state (represented as the dashed line) with respect to
the stage of pregnancy
The data presented are from the following references: Gargosky et al. 1990; Giudice et al. 1993; Nason et al.
1996; Wallace et al. 1997; Sohlstrom et al. 1998; Farmer et al. 2000; Perry et al. 2002; Weber et al. 2007; de Boo
et al. 2008; Van Mieghem et al. 2009.
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pregnantwomenandrats,IGF-IIsecretedasabiologically
inactive pro-peptide undergoes proteolytic cleavage to
become active (Qiu etal. 2005, 2007; Van Mieghem
etal. 2009). Proteolytic activation increases during
pregnancyandcorrelateswithmaternalcirculatingIGF-II
concentrations (Qiu etal. 2005, 2007; Van Mieghem etal.
2009). In addition, the expression, covalent modiﬁcations
and circulating levels of IGFBPs change in the mother
during pregnancy and may inﬂuence circulating IGF
proﬁlesandbioavailability,asreviewedpreviously(Fielder
etal.1990;Donovanetal.1991;Giudiceetal.1993;Nason
etal. 1996; Sohlstrom etal. 1998; Forbes & Westwood,
2008).
The roles of maternal IGFs in fetal growth regulation
Maternal plasma IGFs correlate positively with fetal
growth and birth weight in several species. In mice,
cross-breeding experiments between lines selected for
high or low plasma IGF-I levels reveal that elevated
maternalcirculatingIGF-Iabolishesthenormallynegative
relationship between fetal mass and litter size in
late gestation (Gluckman etal. 1992). Experimental
manipulations of maternal IGFs by exogenous IGF
treatment or elevated endogenous IGF production (via
GH infusion) impacts on fetal growth (Table 1). Fetal
actions of the IGFs depend on species, the speciﬁc
treatment regime (length and timing during pregnancy),
litter size, maternal age, parity, nutritional state and the
time in pregnancy when outcomes were assessed (during
or after treatment). Since IGFs and GH do not cross the
placenta in signiﬁcant quantities (Davenport etal. 1990),
theeffectsoftheIGFsonfetalgrowthmustoccurindirectly
through actions on maternal metabolism and nutrient
partitioning,and/orplacentaldevelopmentandfunction.
Maternal metabolism and nutrient partitioning
In rat dams, positive nitrogen balance during
early pregnancy is correlated with circulating IGF
concentrations (Palmer etal. 1996; Nakago etal. 1999).
Elevating maternal IGF-I by IGF-I or GH administration
in the second half of rat pregnancy stimulated growth
of maternal tissue without an affect on fetal growth
(Table 1: Gargosky etal. 1991; Woodall etal. 1999). In
addition, reducing maternal IGF-I in the second half of
pregnancy using antibodies against GH, repartitioned
maternal muscle protein to growth of the rat pup
(Palmer etal. 1996). This suggests that, in rats, declining
maternal IGF-I concentrations in late pregnancy may
limit maternal anabolic activity to divert substrates to
the gravid uterus. A similar decline in maternal IGF-I
occurs in guinea pigs during late pregnancy although
levels remain higher than pre-pregnancy (Sohlstrom
etal. 1998). Elevating maternal plasma IGF-I in early
guinea pig pregnancy increases uptake of amino acid and
glucose by maternal visceral organs, reduces maternal
adiposity and increases fetal growth, near term long
after cessation of treatment (Sohlstrom etal. 2001;
Sferruzzi-Perri etal. 2006, 2007a,b). Overall, these studies
indicate that maternal IGF-I is important in resource
allocation between maternal tissues and the growing
conceptus but that its endocrine actions are dependent
on species and gestational age.
Inpigs,inwhichplasmaIGF-Iislowerinpregnantthan
non-pregnant states, elevating endogenous IGF-I during
theﬁrsthalfofpregnancybymaternalGHadministration
increased growth of maternal tissues (Table 1: Kelley etal.
1995; Sterle etal. 1995; Okere etal. 1997; Rehfeldt etal.
2001; Schneider etal. 2002; Gatford etal. 2009). In some
of these studies, elevating plasma IGF-I in pig mothers
was also associated with increased plasma concentrations
of glucose, insulin and free fatty acids and enhanced fetal
growth and/or survival (Table 1). These studies suggest
that maternal IGF-I may drive fetal growth by promoting
maternal insulin resistance and thus increasing substrate
availability for the gravid uterus. Certainly, maternal
IGF-I appears to have the most beneﬁcial effects on fetal
development when maternal nutrient supply is limited.
For instance, elevating maternal IGF-I endogenously
enhances maternal back fat loss during pregnancy and
increases fetal growth in undernourished pigs (Gatford
etal. 2000).
In sheep, elevating plasma IGF-I by maternal GH
treatment in early pregnancy increases maternal nutrient
concentrations and sometimes increases fetal weight at
the expense of maternal tissue mass (Table 1: Stelwagen
etal. 1994; Jenkinson etal. 1999; Wallace etal. 2004;
Costine etal. 2005; Koch etal. 2010). However, in
later pregnancy, increasing maternal circulating IGF-I
appears to have no immediate effect on maternal body
composition or fetal weight (Harding etal. 1997). The
extent of IGF-I actions on the mother is dependent on
gestational age, maternal age and nutrition, and whether
the pregnancy is a singleton or twin (Table 1: Costine
etal.2005;Wallaceetal.2006a;K en yonetal.2007;Wright
etal. 2008; Koch etal. 2010). Like the pig, maternal
IGF-I may have most beneﬁt on ovine fetal growth
in adverse maternal environments. For instance, in the
over-nourished adolescent ewe when there is increased
competition for substrates by still-growing maternal
tissues, GH treatment and elevated IGF-I between days
95 to 125 of pregnancy, reduces maternal adiposity and
increasesfetalgrowth(Wallaceetal.2006b).Furthermore,
increasing maternal plasma IGF-I endogenously in late
ovine pregnancy, shifts maternal metabolism in favour
of the conceptus by increasing maternal plasma insulin,
glucose and free fatty acids. This partially prevents the
fetal growth restriction caused by placental embolization
(de Boo etal. 2008).
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Table 1. The impact of elevated maternal plasma IGF-I, IGF-II or GH treatment on the mother and offspring
Gestational age (days) at Outcomes for
Maternal
treatment Species Treatment Study (% of term) Mother Offspring References
IGF-I Mouse D1–19 D19 (95%) ↓ maternal
constraint
↔ fetal weight
litter size and
fetal weight were
no longer
negatively
associated
(Gluckman et al.
1992)
Rat D10–21 D21 (95%) ↑ weight gain
during pregnancy
↔ fetal weight
or viability
(Gargosky et al.
1991; Woodall
et al. 1999)
Guinea pig D20–37 D40 (57%) ↔ weight gain,
food efﬁciency,
body composition
↔ circulating
metabolites
↓ litter size
by 27%
↑ fetal weight
by 6%
(Sohlstrom et al.
2001)
D20–38 D35 (50%) and
D62 (90%)
On D35 and D63:
↑ tissue glucose
and AIB uptake
On D62:
↓ 30–50%
adiposity
On D35 and D62:
↑ fetal weight
by 15–17%
On D62:
↑ fetal viability
↑ plasma a-amino
nitrogen
↓ circulating
cholesterol
(Sferruzzi-Perri
et al. 2006,
2007a,b)
IGF-II Rat D16–22 D22 (100%) ↑ plasma volume
expansion
↔ body weight
↔ fetal weight (Van Mieghem
et al. 2009)
Guinea pig D20–37 D40 (57%) ↔ weight gain,
food efﬁciency
↔ circulating
metabolites
↑ interscapular
fat mass
↑ fetal weight
by 7%
(Sohlstrom et al.
2001)
D20–38 D35 (50%) and
D62 (90%)
On D62:
↔ weight or
body composition
↑ tissue AIB
uptake
↔ circulating
metabolites
On D62:
↑ fetal viability
↑ fetal weight by
11% ↑ circulating
a-amino nitrogen
(Sferruzzi-Perri
et al. 2006,
2007a,b)
Leu27 IGF-II Guinea pig D20–38 D62 (90%) ↔ weight gain
↓ adiposity by
10–30%
↔ tissue uptake
of glucose or AIB
↔ circulating
metabolites
↔ fetal viability
↑ fetal weight by
11%
↑ circulating
a-amino nitrogen
↓ circulating
cholesterol
↓ circulating fatty
acids
(Sferruzzi-Perri
et al. 2008)
GH Rat D10–20 D20 (90%) ↑ weight gain ↔ fetal weight or
body composition
↔ postnatal
growth
(Woodall et al.
1999)
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Table 1 Continued
Gestational age (days) at Outcomes for
Maternal
treatment Species Treatment Study (% of term) Mother Offspring References
GH Pig D10–27 D28 (25%) ↔ body weight
↑ lean body mass
↑ circulating
insulin, glucose
and free fatty
acids
↑ fetal weight
of runts
(Rehfeldt et al.
2001; Schneider
et al. 2002)
D25–50 D50 (45%) ↑ weight gain in
sows
↔ weight gain in
gilts In both sows
and gilts:
↓ circulating urea
In both sows and
gilts:
↑ fetal weight by
11%
(Gatford et al.
2009)
D28–40 D41 (35%),
P1 (100%)
↑ weight on D41
but ↓ by D105
↑ embryonic
survival
↔ fetal weight
↑ fetal and
postnatal CR
length
(Kelley et al.
1995; Sterle et al.
1995)
D30–70 D113 (100%) ND ↔ fetal weight
↔ fetal viability
(Okere et al.
1997)
D97–115 D113 (100%) ↑ circulating
glucose
↑ circulating
insulin
↑ circulating fatty
acids
↔ birth weight (Kveragas et al.
1986)
Sheep D7–30
Singleton and
twin
pregnancies
P1 (100%) ND In singleton
but not twin
pregnancies:
↑ birth weights
by 10%
(Costine et al.
2005; Koch et al.
2010)
D35–55
Only twin
pregnancies
D55 (37%) ↔ weight gain ↔ fetal weight (Wright et al.
2008)
D70–84 or
D98–112
Singleton and
twin
pregnancies
D85 (56%) or
D113 (75%)
↔ energy intake
↑ uterine weight
↑ circulating
insulin
↑ circulating fatty
acids
↑ circulating
glucose
D70–84:
↔ fetal weight
D98–112:
↑ fetal weight by
9–11% (similar
impacts on
singles and twins)
(Jenkinson et al.
1999)
D35–80 D81 (54%) ↔ food intake
↔ weight gain
↓ adiposity by
∼20%
↑ liver mass
↑ circulating
insulin, glucose
and fatty acids
↓ circulating
leptin
↔ fetal weight (Wallace et al.
2004)
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Table 1 Continued
Gestational age (days) at Outcomes for
Maternal
treatment Species Treatment Study (% of term) Mother Offspring References
GH Sheep D97–124 D125 (83%),
P1 (100%)
↔ weight gain
↓ proportion of
body fat
↔ fetal weight (Stelwagen et al.
1994)
D125–134 D134 (90%) ↔ energy intake
↔ body weight
↓ circulating urea
↑ circulating
insulin
↔ fetal weight (Harding et al.
1997)
AIB,aminoisobutyricacid;CR,crown–rump;D,dayofpregnancy;ND,notdetermined;P,postnatalday.Forstudiesinsheep,pregnancies
were singleton or otherwise stated. Average gestational length in days in: mice, 20; rats, 22; guinea pigs, 70; pigs, 112 and sheep, 150.
Compared to IGF-I, there is less information about
the role of endocrine IGF-II in maternal metabolism
and substrate partitioning (Table 1). In guinea pigs,
elevating maternal IGF-II in early to mid pregnancy did
not affect maternal body composition, whilst uptake of
amino acids by maternal visceral organs was increased
andfetalgrowthenhancednearterm(Sferruzzi-Perrietal.
2006, 2007a,b). In contrast to native IGF-II, treatment
of guinea pig dams with a synthetic analogue of IGF-II
that selectively binds to IGF2R (Leu27–IGF-II), reduced
maternal adiposity in late pregnancy without effects on
substrate uptake by maternal tissues (Sferruzzi-Perri etal.
2008). The effects of Leu27–IGF-II on maternal body
compositionweresimilartothoseofIGF-I,suggestingthat
some IGF-I-speciﬁc effects may be due to displacement of
endogenous IGF-II from the IGF2R and its subsequent
interaction with IGF1R and the InsR. In rats, IGF-II
treatment in mid to late pregnancy increased maternal
blood volume expansion without impacting on fetal
growth(Table1:VanMieghemetal.2009).Thus,maternal
endocrineIGF-IImayinﬂuencefetalgrowthbyregulating
maternal metabolic and cardiovascular adaptations to
pregnancy; however, further studies are warranted.
Placental development and function
Maternal endocrine IGFs may also affect fetal growth via
placental actions. In addition to transporting nutrients,
theplacentamaymodulatefetaldevelopmentbysecreting
hormones, either into the umbilical circulation to directly
affect fetal metabolism and growth, or into the maternal
circulation to alter maternal metabolism and substrate
availability for placental transfer. The placenta expresses
IGF1R,IGF2RandInsRinseveralspeciesandIGF1R–InsR
hybrid in the human placenta (Zhou & Bondy, 1992;
Soos etal. 1993; Fang etal. 1997; Hiden etal. 2006;
Sferruzzi-Perrietal.2006;Pringle&Roberts,2007).More
speciﬁcally,inwomenandguineapigs,theIGFandinsulin
receptors are localised to the syncytiotrophoblast layer
bathed in maternal blood (Fang etal. 1997; Hiden etal.
2006; Sferruzzi-Perri etal. 2006). This permits endocrine
regulation of placental growth and function by maternal
IGFs (Table 2).
IGF-I and IGF-II prevent apoptosis and enhance
proliferation and migration in human placental villous
explants, primary trophoblast cultures or trophoblast cell
lines from early pregnancy and term (Table 2: Irving
& Lala, 1995; Hamilton etal. 1998; McKinnon etal.
2001; Lacey etal. 2002; Smith etal. 2002; Hills etal.
2004; Kabir-Salmani etal. 2004; Qiu etal. 2005; Forbes
etal. 2008). Similarly, IGF-I stimulates proliferation
and migration, whilst IGF-II promotes differentiation
of murine ectoplacental cone trophoblast in culture
(Kanai-Azumaetal.1993).Furthermore,IGF-IIpromotes
migration of ovine trophoblast cells in vitro (Kim etal.
2008).
In guinea pigs, maternal plasma IGF-I and IGF-II
correlate positively with placental surface area for
exchange and negatively with barrier thickness (Roberts
etal. 2008). Treatment of guinea pig dams with either
IGF in early to mid pregnancy increases fetal weight near
term (Sferruzzi-Perri etal. 2006). Whilst there was no
sustained effect of either IGF on placental weight, IGF-II
increased the volume and surface area of the exchange
region in late gestation (Table 2: Sferruzzi-Perri etal.
2006). Development of the placental exchange region
was further enhanced when the IGF2R-selective synthetic
analogue, Leu27–IGF-II was administered maternally
(Sferruzzi-Perri etal. 2008). This suggests that maternal
IGF-IIin earlygestation may act, in part, via the IGF2R to
enhance functional development of the placenta.
In addition to stimulating placental growth, maternal
endocrine IGFs may inﬂuence fetal growth by altering
activity of the placental nutrient transporters. Both IGF-I
and IGF-II stimulate glucose and amino acid uptake in
human trophoblast in vitro (Kniss etal. 1994; Karl, 1995;
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Table 2. The impact of IGFs on placental growth and function in vitro and in vivo
Treatment Species Treatment (txt) Analysis day Placental outcome References
IGF-I Mouse In vivo: maternal txt
D1–19
D19 ↔ weight (Gluckman et al. 1992)
In vitro: primary
ectoplacental cone
trophoblast
1st trimester ↑ proliferation
↑ migration
(Kanai-Azuma et al.
1993)
Rat In vivo: maternal txt
D10–21
D21 ↔ weight (Gargosky et al. 1991;
Woodall et al. 1999)
Guinea
pig
In vivo: maternal txt
D20–37
D40 ↑ weight by 10% (Sohlstrom et al. 2001)
In vivo: maternal txt
D20–38
D35 and D62 ↔ weight or structure
↑ transfer of glucose
and AIB
(Sferruzzi-Perri et al.
2006, 2007a,b)
Sheep In vivo: maternal txt
for 4 h on ∼D132
D132 ↑ lactate production (Liu et al. 1994)
Human In vitro: villous
explants
1st trimester ↑ trophoblast proliferation
↑ extravillous trophoblast
migration
↓ trophoblast apoptosis
(Maruo et al. 1995;
Lacey et al. 2002;
Forbes et al. 2008)
In vitro: villous
explants
1st trimester ↑ secretion of hCG and hPL (Maruo et al. 1995),
In vitro: primary
trophoblast
1st trimester ↑ proliferation
↑ migration
↑ invasion
(Hamilton et al. 1998;
Hills et al. 2004;
Kabir-Salmani et al.
2004)
In vitro: primary
villous trophoblast
1st trimester
and term
↑ glucose and amino
acid uptake
(Kniss et al. 1994; Karl,
1995; Roos et al. 2009)
In vitro: villous
explants
Term ↓ release of
vasoconstrictors
(Siler-Khodr et al.
1995)
In vitro: primary
villous and
syncytialised
trophoblast
Term ↓ TNFα-a n dI F N γ-induced
apoptosis
(Smith et al. 2002)
IGF-II Mouse In vitro: primary
ectoplacental cone
trophoblast
1st trimester ↑ differentiation into
giant cells
(Kanai-Azuma et al.
1993)
Rat In vivo: maternal txt
D16–22
D22 ↑ 29% volume of
junctional zone
(Van Mieghem et al.
2009)
Sheep In vitro: primary
mononuclear
trophoblast
1st trimester ↑ migration (Kim et al. 2008)
Guinea
pig
In vivo: maternal txt
D20–37
D40 ↑ weight by 9% (Sohlstrom et al. 2001)
In vivo: maternal txt
D20–38
D35 and D62 ↔ weight
↓ area and proportion
of the interlobium
↑ labyrinthine area,
proportion and volume
↑ surface area for
exchange
↔ thickness of the
trophoblast barrier
for exchange
↑ transfer of glucose
(Sferruzzi-Perri et al.
2006, 2007a,b)
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Table 2 Continued
Treatment Species Treatment (txt) Analysis day Placental outcome References
IGF-II Human In vitro: villous
explants
1st trimester ↑ trophoblast proliferation
↑ syncytial regeneration
↑ extravillous trophoblast
cell migration
↓ trophoblast apoptosis
(Lacey et al. 2002;
Forbes et al. 2008)
In vitro:p r i m a r y
trophoblast
1st trimester ↑ proliferation
↑ migration
↑ invasion
(Irving & Lala, 1995;
Hamilton et al. 1998;
McKinnon et al. 2001;
Hills et al. 2004; Qiu
et al. 2005)
In vitro:p r i m a r y
villous trophoblast
1st trimester
and term
↑ glucose and amino acid
uptake
(Kniss et al. 1994; Karl,
1995)
AIB, amino isobutyric acid; D, day of pregnancy; hCG, human chorionic gonadotropin; hPL, human placental lactogen; txt, treatment.
IGF-I IGF-II
Growth Metabolism
Substrate
available
Maternal adaptation to pregnancy
Growth
Substrate
transfer 
Endocrine
function
Placenta
Other
hormones
Substrate
supply
Endocrine
environment 
Fetus
Growth
Figure 2. The proposed actions of maternal circulating IGFs on the mother and placenta that drive fetal
growth
Circulating IGFs inﬂuence maternal tissue growth and metabolism and thereby modulate nutrient availability
for conceptus growth. Maternal IGFs also regulate placental morphogenesis, substrate transport and hormone
secretion, which inﬂuence fetal growth by indirect effects on maternal substrate availability, or by direct impacts
on placental capacity to supply nutrients to the fetus and the fetal endocrine environment. These actions of plasma
IGFs on the mother and placenta inﬂuence fetal growth, metabolism and endocrine state, which in turn, may
signal back to the placenta to alter its phenotype.
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Roos etal. 2009). In the late pregnant ewe, acute maternal
IGF-Itreatmentaltersplacentalmetabolicfunction,which
suggestsenhancedglucoseandlactatedeliverytothefetus
(Liu etal. 1994). In guinea pigs, elevated maternal plasma
IGF-I or IGF-II during early to mid pregnancy increases
placental capacity to deliver glucose and/or amino acids
to the fetus in late gestation (Table 2: Sferruzzi-Perri etal.
2006, 2007a,b). Placental substrate transfer was increased
in late gestation, partly due to enhanced expression of
nutrient transporters by IGF-I in mid pregnancy and
improved development of the exchange region by IGF-II
in late pregnancy (Sferruzzi-Perri etal. 2006, 2007b). In
culture,IGF-Ipreventsthereleaseofthevaso-constrictors
prostaglandin E and F, and thromboxane, by the term
human placenta (Table 2: Siler-Khodr etal. 1995).
In vivo,theseeffectscouldinﬂuenceutero-placentalblood
ﬂow and substrate transfer in late gestation. Indeed,
reduced maternal circulating IGF-I or increased maternal
circulating inactive pro-IGF-II in women, are associated
with abnormal placental blood ﬂows and small for
gestationalageandgrowth-restrictedbabies(Holmesetal.
1997; Qiu etal. 2005).
IGFs enhance placental secretion of hormones
including progesterone, human chorionic gonadotrophin
and PL in vitro (Maruo etal. 1995). In addition, IGF-II
simulates the differentiation of hormone-producing cells
in murine and ovine trophoblast in vitro and the
development of the endocrine trophospongial zone of the
rat placenta, in vivo (Kanai-Azuma etal. 1993; Kim etal.
2008; Van Mieghem etal. 2009). IGF-induced changes
in placental hormone production may inﬂuence fetal
growth directly or indirectly. For instance, PL secreted
into the umbilical circulation promotes secretion of
growth promoting hormones, such as insulin and IGF-I
and IGF-II in the fetus, whilst in the mother, PL and
progesteroneinducematernalinsulinresistance,favouring
glucose delivery to the fetus for growth (Butte, 2000;
Handwerger & Freemark, 2000; Karabulut etal. 2001).
Thus,maternalendocrineIGFsmayinﬂuencefetalgrowth
byalteringplacentaldevelopment,hormonesecretionand
substrate transport.
Conclusions and perspectives
IGFsinthematernalcirculationareemergingasimportant
regulators of fetal growth via their actions on both the
motherandtheplacenta(Fig.2).Theyinﬂuencematernal
tissue growth and metabolism and, thereby, modulate
nutrient availability for conceptus growth. They also
regulateplacentalmorphogenesis,substratetransportand
hormone secretion, which inﬂuence fetal growth either
via indirect effects on maternal substrate availability, or
through direct impacts on fetal nutrient supply and its
endocrine environment (Fig.2). In turn, changes in fetal
growth, metabolism and endocrine state induced by the
actions of maternal plasma IGFs may signal back to the
placenta to alter its phenotype further (Harding etal.
1994;Constanciaetal.2005).Overall,maternalIGF-Iand
IGF-II may have complementary but overlapping roles
in optimising fetal nutrient acquisition for growth and
survival. Maternal IGF-I appears to act predominantly
on maternal tissues to inﬂuence substrate availability,
whereas maternal IGF-II acts on the placenta to inﬂuence
substratedeliverytothefetus(Fig.2).Therelativebalance
of IGF actions on the mother and placenta in regulating
fetal growth depends not only on the abundance of the
two IGFs, but also on the species, stage of pregnancy,
and age and nutritional state of the mother. Maternal
IGF administration may, therefore, have beneﬁts to the
food and livestock industry by providing a means of
improving animal productivity; however, further studies
are warranted. Furthermore, in animal models of intra-
uterine growth, elevating maternal IGF concentrations
appearstoimprovefetalgrowth,suggestingthepossibility
for clinical translation (Gatford etal. 2000; Wallace
etal. 2006b;d eB o oetal. 2008). Before this approach
could be used therapeutically to improve fetal growth
in compromised human pregnancies, further studies are
required to identify the potential long-term effects on
both the mother and her offspring with respect to tissue
growth and endocrine function. Furthermore, little is
known about the regulation of IGF synthesis or the
identity of molecular mediators of IGF actions on the
placenta and mother. Thus, future research could aim to
antagonise IGFs actions and/or their speciﬁc receptors
and determine the effect/s on pregnancy and postnatal
outcomes,sothatperhapsIGF-IorIGF-IImaybetargeted
speciﬁcally to the placenta and/or particular maternal
tissues. Moreover, researchers could explore therapeutic
options of increasing endogenous IGF synthesis, perhaps
by nutritional means. Since maternal IGF treatment is
likely to be most efﬁcacious in early gestation, before the
onsetofimpairedfetalgrowth,anadditionalfocusshould
be developing better methods for identifying pregnancies
at risk of intrauterine growth restriction.
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